Arete Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Arete Therapeutics launched in 2003 with a straightforward therapeutic and commercial goal: to develop a new treatment for high blood pressure that works by blocking the s-EH enzyme. Arete began enrolling patients for its first human trial in November 2007, and its oral inhibitor of s-EH proved safe. By the time the safety data were released a year later, Arete's strategy had been further refined and the company was envisioning the compound as a potential therapy for metabolic syndrome. Based on data from preclinical studies, Arete now posits that its therapy can become a treatment for type 2 diabetes.
You may also be interested in...
Start-Up Previews (03/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Treating Late-Stage Prostate Cancer," features profiles of AndroBioSys, Bellicum Pharmaceuticals, Colby Pharmaceuticals and Med Discovery. Plus these Start-Ups Across Health Care: AeonClad Biomedical, Arete Therapeutics, Bonovo Orthopedics and Thrasos Therapeutics.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.